DBPR112 is an inhibitor of EGFR and dual-mutant EGFRL858R/T790M (IC50s = 15 and 48 nM, respectively). It is selective for these kinases over 384 other kinases but does inhibit 11 additional kinases, including JAK3, Blk, and bone marrow tyrosine kinase on chromosome X (BMX), at 10,000 nM. DBPR112 reduces the...

Description: DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM for EGFRWT and 48 nM for EGFRL858R/T790M, capable of occupying the ATP-binding site and demonstrating significant antitumor efficacy. Target: EGFR. Smiles:...